Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 76

Results For "NGO"

817 News Found

We are marketing all our products globally: Samit Jain, MD, PLUSS
interviews | October 25, 2021

We are marketing all our products globally: Samit Jain, MD, PLUSS

Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business

ISA celebrates October as stroke awareness month
Healthcare | October 21, 2021

ISA celebrates October as stroke awareness month

India reports 18 lakh stroke cases a year with 25 per cent patients below the age of 50

Sage Therapeutics and Biogen plan to submit a New Drug Application (NDA) for zuranolone
Biotech | October 21, 2021

Sage Therapeutics and Biogen plan to submit a New Drug Application (NDA) for zuranolone

Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD

Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
Biotech | October 13, 2021

Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients

New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials

Covaxin for kids gets nod, final approval awaited
Drug Approval | October 12, 2021

Covaxin for kids gets nod, final approval awaited

The two doses of Covaxin are likely to be administered to children with a gap of 28 days

Roche’s Alzheimer antibody granted U.S. FDA Breakthrough Therapy Designation
Biotech | October 09, 2021

Roche’s Alzheimer antibody granted U.S. FDA Breakthrough Therapy Designation

Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022

WHO gives its go-ahead for first-ever malaria vaccine
Drug Approval | October 07, 2021

WHO gives its go-ahead for first-ever malaria vaccine

It recommends using the vaccine to prevent the spread of the disease

Moderna to build mRNA facility in Africa
Biotech | October 07, 2021

Moderna to build mRNA facility in Africa

The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come

AstraZeneca requests Emergency Use Authorisation for drug to prevent Covid
Biotech | October 05, 2021

AstraZeneca requests Emergency Use Authorisation for drug to prevent Covid

The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)

Moderna Science Centre coming up in Cambridge, MA
Biotech | October 04, 2021

Moderna Science Centre coming up in Cambridge, MA

The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge

Latest Stories

Sanofi’s Amlitelimab delivers in Phase 3 trials, heads for global filings

Trelegy Ellipta gets green light in China for adults with uncontrolled asthma

Hongene Biotech bags Gates Foundation grant to boost global mRNA vaccine access

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging